Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

BIOMARKER:

PD-L1 overexpression + CD8 overexpression

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related biomarkers:

‹

PD-L1 expression (356)

PD-L1 overexpression (181)

PD-L1 underexpression (46)

PD-L1 negative (28)

HER-2 negative + PD-L1 expression (12)

CD8 overexpression (9)

CD8 expression (8)

CD8 positive (7)

HER-2 positive + PD-L1 expression (3)

CD8 underexpression + HAVCR2 overexpression (3)

HR negative + PD-L1 expression (2)

MSLN overexpression + PD-L1 overexpression (2)

PD-L1 expression + CD68 positive (2)

PD-L1 expression + HER-2 overexpression (2)

PD-L1 expression + PVR expression (2)

TTF1 expression + PD-L1 expression (2)

miR-625-5p underexpression + PD-L1 overexpression (2)

AXL overexpression + PD-L1 expression (1)

CGAS overexpression + PD-L1 overexpression (1)

CMTM4 expression + PD-L1 expression (1)

CMTM6 expression + PD-L1 expression (1)

CMTM6 overexpression + PD-L1 overexpression (1)

CXCL12 expression + PD-L1 underexpression (1)

HLA-A underexpression + PD-L1 expression (1)

HR positive + PD-L1 expression (1)

IGFBP2 overexpression + PD-L1 overexpression (1)

MHC-II overexpression + PD-L1 negative (1)

MHC-II overexpression + PD-L1 underexpression (1)

NKX2-1 expression + PD-L1 expression (1)

NR1H4 overexpression + PD‑L1 underexpression (1)

NT5E overexpression + PD-L1 expression (1)

PD-1 underexpression + PD-L1 overexpression (1)

PD-L1 expression + CD14 positive (1)

PD-L1 expression + CD47 expression (1)

PD-L1 expression + CD8 negative + GZMB negative (1)

PD-L1 expression + CD8 positive (1)

PD-L1 expression + CTLA4 expression (1)

PD-L1 expression + MTOR overexpression (1)

PD-L1 expression + REV3L overexpression (1)

PD-L1 overexpression + APOBEC3B overexpression (1)

PD-L1 overexpression + CCL5 overexpression (1)

PD-L1 overexpression + CD163 underexpression (1)

PD-L1 overexpression + ER positive (1)

PD-L1 overexpression + GZMA overexpression (1)

PD-L1 overexpression + LAG3 expression + CTAG1B expression (1)

PD-L1 overexpression + PD-L2 underexpression (1)

PD-L1 overexpression + SOX2 overexpression (1)

RBM17 expression + PD-L1 expression (1)

RET positive + PD-L1 overexpression (1)

SNX20 overexpression + PD-L1 overexpression (1)

STK11 underexpression + PD-L1 overexpression (1)

TFRC overexpression + PD-L1 underexpression (1)

TNFSF4 overexpression + PD-L1 overexpression (1)

TTF1 expression + PD-L1 overexpression (1)

PD-1 overexpression + CD8 positive (1)

PD-1 positive + TIGIT positive + CD8 positive (1)

TCF7 overexpression + CD8 overexpression (1)

TNFRSF9 positive + CD8 positive (1)

HER-2 negative + HR negative + PD-L1 expression (0)

PD-L1 expression + HER-2 expression (0)

PD-L1 expression + LAG3 expression (0)

PD-L1 expression + TTF1 expression (0)

TMB + PD-L1 expression (0)

CD8 negative (0)

PD-L1 expression (356)

PD-L1 overexpression (181)

PD-L1 underexpression (46)

PD-L1 negative (28)

HER-2 negative + PD-L1 expression (12)

CD8 overexpression (9)

CD8 expression (8)

CD8 positive (7)

HER-2 positive + PD-L1 expression (3)

CD8 underexpression + HAVCR2 overexpression (3)

HR negative + PD-L1 expression (2)

MSLN overexpression + PD-L1 overexpression (2)

PD-L1 expression + CD68 positive (2)

PD-L1 expression + HER-2 overexpression (2)

PD-L1 expression + PVR expression (2)

TTF1 expression + PD-L1 expression (2)

miR-625-5p underexpression + PD-L1 overexpression (2)

AXL overexpression + PD-L1 expression (1)

CGAS overexpression + PD-L1 overexpression (1)

CMTM4 expression + PD-L1 expression (1)

CMTM6 expression + PD-L1 expression (1)

CMTM6 overexpression + PD-L1 overexpression (1)

CXCL12 expression + PD-L1 underexpression (1)

HLA-A underexpression + PD-L1 expression (1)

HR positive + PD-L1 expression (1)

IGFBP2 overexpression + PD-L1 overexpression (1)

MHC-II overexpression + PD-L1 negative (1)

MHC-II overexpression + PD-L1 underexpression (1)

NKX2-1 expression + PD-L1 expression (1)

NR1H4 overexpression + PD‑L1 underexpression (1)

NT5E overexpression + PD-L1 expression (1)

PD-1 underexpression + PD-L1 overexpression (1)

PD-L1 expression + CD14 positive (1)

PD-L1 expression + CD47 expression (1)

PD-L1 expression + CD8 negative + GZMB negative (1)

PD-L1 expression + CD8 positive (1)

PD-L1 expression + CTLA4 expression (1)

PD-L1 expression + MTOR overexpression (1)

PD-L1 expression + REV3L overexpression (1)

PD-L1 overexpression + APOBEC3B overexpression (1)

PD-L1 overexpression + CCL5 overexpression (1)

PD-L1 overexpression + CD163 underexpression (1)

PD-L1 overexpression + ER positive (1)

PD-L1 overexpression + GZMA overexpression (1)

PD-L1 overexpression + LAG3 expression + CTAG1B expression (1)

PD-L1 overexpression + PD-L2 underexpression (1)

PD-L1 overexpression + SOX2 overexpression (1)

RBM17 expression + PD-L1 expression (1)

RET positive + PD-L1 overexpression (1)

SNX20 overexpression + PD-L1 overexpression (1)

STK11 underexpression + PD-L1 overexpression (1)

TFRC overexpression + PD-L1 underexpression (1)

TNFSF4 overexpression + PD-L1 overexpression (1)

TTF1 expression + PD-L1 overexpression (1)

PD-1 overexpression + CD8 positive (1)

PD-1 positive + TIGIT positive + CD8 positive (1)

TCF7 overexpression + CD8 overexpression (1)

TNFRSF9 positive + CD8 positive (1)

HER-2 negative + HR negative + PD-L1 expression (0)

PD-L1 expression + HER-2 expression (0)

PD-L1 expression + LAG3 expression (0)

PD-L1 expression + TTF1 expression (0)

TMB + PD-L1 expression (0)

CD8 negative (0)

›

11ms

Global burden, risk factors, clinicopathological characteristics, molecular biomarkers and outcomes of microsatellite instability-high gastric cancer. (PubMed, Aging (Albany NY))

Moreover, giving MSI-H tumors are often diagnosed at early stage and have favorable outcomes, less aggressive treatment strategies may be considered in clinical practice. In summary, this panoramic review may assist in design and/or interpretation of clinical trials, provide references in drug development, and constitute complementary information in drafting the clinical practice guideline.

11 months ago

Journal • Tumor mutational burden • Microsatellite instability • MSi-H Biomarker • PD(L)-1 Biomarker • IO biomarker

|

HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53) • TMB (Tumor Mutational Burden) • MSI (Microsatellite instability) • CD8 (cluster of differentiation 8)

|

HER-2 positive • TP53 mutation • KRAS mutation • TMB-H • MSI-H/dMMR • PD-L1 overexpression • HER-2 overexpression • HER-2 mutation • CD8 overexpression • PD-L1 overexpression + CD8 overexpression • PD-L1 mutation